THE COMMERCIAL CRUCIBLE

Halfway through 2026, the commercial environment for medical technology in the United States is defined by a collision of forces that, individually, would each have been the story of the year. A tariff regime that has changed legal basis three times in twelve months. A hospital customer base running one-to-three percent operating margins against supply expense growth approaching ten percent, with a legislated Medicaid revenue cliff arriving in 2027. A Medicare policy reset that is simultaneously accelerating coverage for breakthrough devices and dismantling the add-on payment pathways that made breakthrough status financially valuable. And a structural migration of procedures to ambulatory settings where buyers demand prices fifteen percent lower and will switch brands to get them. For pricing and contracting leaders, this is the crucible: the period in which commercial models built for the 2010s are being melted down and recast.

Five conclusions frame this report.

First, the tariff era has normalized without broad price pass-through. Large manufacturers absorbed 2025 tariff costs of roughly $100–500 million each rather than reprice, constrained by fixed-price GPO contracts and procedure-based reimbursement; 2026 has so far been cushioned by refunds of invalidated IEEPA duties even as new Section 301 tariffs of 10–12.5% took effect in July. The Section 232 medical device decision expected around September 2026 is the biggest near-term risk event (MedTech Dive; Covington).

Second, the balance of negotiating power has shifted decisively to the buyer. Hospitals enter 2026 with year-to-date margins of 1.3–2.5%, supply expenses that grew 9.9% in 2025, and a $1 trillion federal funding reduction on the horizon. Their group purchasing organizations have converted cost pressure into infrastructure: integrated spend-management platforms, procedural analytics that expose physician-level variation, bill-only automation, and price benchmarks built from newly hardened CMS transparency files (Kaufman Hall; AHA; KFF).

Third, Medicare policy now trades payment generosity for coverage speed. The new RAPID pathway promises national coverage within roughly two months of FDA authorization, but the breakthrough shortcuts to new technology add-on payments and transitional pass-through payments are being repealed, restoring the substantial-clinical-improvement evidence bar for premium payment (CMS; Holland & Knight).

Fourth, the site-of-care shift is now scheduled, not speculative. CMS has put the elimination of the Inpatient-Only list on a three-year timetable ending in 2028 and added 560 procedures to the ASC covered list for 2026 alone, including cardiac ablation. Device volume is moving to buyers who are structurally more price-sensitive and organizationally simpler — and to purchasing groups built to aggregate them (McDermott+; Bain).

Fifth, commercial capability is becoming the differentiator. With list-price growth capped near GPO inflation forecasts of 2.4–2.8% and net-price erosion continuing, the winners of 2026–2027 are competing on contract architecture rather than list price: outcome warranties, usage-based capital placement (28.8% of Intuitive’s 2025 robot placements were usage-based), enterprise value partnerships, AI-assisted pricing and tender intelligence, and disciplined contract-leakage management in an industry where 96% of manufacturers still track contracts in spreadsheets (Intuitive; Business Wire).

The sections that follow examine each force in turn, the tariff whipsaw and its contracting aftermath, hospital economics and the procurement machine, the CMS policy reset, the ambulatory migration, and the commercial model innovation now separating leaders from laggards, and close with a set of strategic imperatives and a watch list for the second half of 2026.

The Tariff Whipsaw: A New Cost Base Without a New Price Base

1.1 Three legal regimes in twelve months

No input to MedTech commercial planning has been less stable than trade policy. The 2025 “reciprocal” tariffs imposed under the International Emergency Economic Powers Act (IEEPA) — a universal 10% baseline from April 2025, with China-origin rates that peaked as high as 245% on some lines such as enteral syringes, were the initial cost shock (Premier). In February 2026 the Supreme Court ruled 6–3 in Learning Resources, Inc. v. Trump that IEEPA does not authorize tariffs, invalidating duties of which roughly $134 billion had been collected (Medical Economics). Within days the administration pivoted to Section 122 balance-of-payments authority and a 10% global tariff; that authority expired at its statutory 150-day limit on July 24, 2026, and was replaced the same day by new Section 301 duties of 10–12.5% on products from roughly 60 economies — duties with no statutory expiration and no rate cap (Section 122 tracker; Skadden).

The larger overhang is the Section 232 national-security investigation into imports of medical consumables, equipment and devices that Commerce self-initiated in September 2025, covering everything from syringes and IV bags to pacemakers, insulin pumps and imaging systems. A decision is expected around mid-September 2026. The precedent is not reassuring: parallel Section 232 actions produced 100% tariffs on certain patented pharmaceuticals effective July 31, 2026, and 25% on advanced semiconductors from January 2026. Pharmaceutical ingredients won exemptions; medical devices, as of August 2026, have not (Supply Chain Dive; Covington; MichBio).

1.2 What tariffs actually cost — and the 2026 refund windfall

The realized P&L damage of 2025 landed at roughly half of initial guidance across the large caps, as trade deals de-escalated and mitigation programs matured. The 2026 picture is stranger still: the Court of International Trade ordered refunds of invalidated IEEPA duties, and PwC estimates up to $2.6 billion is recoverable by MedTech companies. Refunds are now flowing through earnings — Philips booked a €186 million refund in Q2 2026, GE HealthCare $129 million, and Stryker reported a net tariff benefit — even as the new Section 301 duties accrue on current imports (MedTech Dive; MD+DI; Motley Fool).

Company tariff disclosures from earnings calls and trade press, 2025 through August 2026. Sources: MedTech Dive earnings coverage; MD+DI; company transcripts.

1.3 Why the costs did not become prices

The most commercially significant fact of the tariff era is what did not happen: broad list-price pass-through. PwC’s assessment one year in was blunt — companies are “not passing the prices on to customers. They’re just bearing the brunt of it and trying to find efficiency.” Two structural constraints explain this. Devices are priced inside procedure reimbursement, so a manufacturer cannot reprice the way a drugmaker can when the hospital is still paid the same amount for the knee replacement. And the installed base of multi-year, fixed-price GPO and IDN contracts left little legal room to move: when vendors experimented with invoice-level “fees or stipends” in spring 2025, large systems simply refused them — Universal Health Services reported ignoring such surcharges, with roughly 75% of its supply spend protected by fixed contract prices (MedTech Dive; Axios).

Manufacturers instead built a mitigation toolkit: tariff modeling and country-of-origin engineering, dual sourcing, exploiting the Nairobi Protocol’s duty-free treatment of articles for the handicapped (pacemakers, prosthetics, insulin pumps), and selective reshoring — GE HealthCare moved PET/CT production to the US, and industry output shifted toward North Carolina, Mexico and Costa Rica. KPMG’s characterization captures the mood: leaders now treat tariffs like interest rates, “expected operating conditions” to be managed rather than emergencies to be escaped (MedTech Dive; MD+DI).

The contracting battleground now moves to renewal cycles. As the 2024–25 vintage of firm-price agreements rolls off, suppliers will attempt to reset baselines that reflect the new cost base, and buyers are prepared: Premier has told members to demand country-of-origin transparency and documented evidence before accepting any tariff-related price change, and the American Hospital Association is lobbying for outright medical exemptions from the Section 301 duties, noting hospitals cannot pass costs through because their own payment contracts are fixed in advance. Whether tariff-adjustment clauses — largely absent from legacy agreements — become standard in 2026–27 contracts is one of the defining drafting questions of this cycle (Premier; AHA).

2. The Buyer’s Market: Hospital Economics and the Procurement Machine

2.1 A customer that cannot afford you

The starting point for every 2026 negotiation is the customer’s income statement. Total hospital expenses grew 7.5% in 2025 — roughly double the growth in hospital prices — with medical supply expenses up 9.9% and drug expenses up 13.6%. Kaufman Hall’s flash data show adjusted year-to-date operating margins of just 1.3% through February 2026, recovering only to about 2.5% by April (versus 3.6% a year earlier), with non-labor expense up 8% and bad debt and charity care up 22% year-to-date. Kaufman Hall calls this the “new normal”: payer mix eroding from private to public, providers “working more but being paid less” (AHA; Kaufman Hall; Fierce Healthcare).

Layered on top is the July 2025 reconciliation law (the One Big Beautiful Bill Act), which cuts federal Medicaid spending by roughly $793 billion and ACA marketplace spending by $268 billion over ten years, with projected coverage losses of 11–16 million people and possible Medicare sequestration of about $500 billion including a 4% hospital payment cut. The cuts bite from 2027 and are backloaded — but systems are pre-positioning now: Fitch-tracked systems are aggressively managing non-labor costs, redirecting capital from inpatient facilities toward outpatient access points and IT, and deploying AI against labor and supply chain costs. Roughly 39% of hospitals already ran negative margins in 2023, rising to 44% among rural facilities (KFF; HFMA).

The practical consequence for suppliers: supply chain is the hospital’s most actionable P&L lever, and GPO inflation forecasts function as de facto ceilings on achievable price increases. Vizient projects overall supply chain price growth of 2.41% for contracts effective July 2026 and 2.78% for the July 2026–June 2027 window, and its Winter 2026 outlook concedes that “many traditional cost levers are reaching their limits” — pushing buyers toward utilization management, standardization and total-cost-of-ownership analysis rather than price negotiation alone (Vizient; Vizient Winter 2026).

The gap between realized supply expense growth (~10%) and contracted price inflation (~2.4%) reflects volume, mix and tariff effects — and explains why buyers treat any list increase above ~3% as an opening position.

2.2 The GPO landscape reorganizes

All three national purchasing giants repositioned in this cycle. Premier completed a $2.6 billion take-private with Patient Square Capital in November 2025, freeing it from the quarterly optics of fee-share compression as it pivots from admin-fee GPO economics toward technology and advisory revenue. Vizient used the April 2026 IDN Summit to launch an integrated spend-management stack, a certified procure-to-pay solution, a Procedural Analytics product linking price, encounter and procedural data to attack physician-level variation, and a tiered partnership program bundling analytics, contracting and execution. HealthTrust continues to lean on its committed model — one price for all, fixed for the contract term, across a portfolio covering some 85% of a provider’s typical spend — the hardest environment for challengers to shift share, and the most decisive when a vendor wins (Healthcare Dive; Vizient/Businesswire; HealthTrust).

Beneath the national GPOs, large IDNs keep expanding direct and self-contracting for strategic categories while reserving national agreements for commodities, and high-cost novel therapies increasingly move through direct-from-manufacturer models entirely. For suppliers this fragments the negotiation map: the same product may face a committed national tender, a regional aggregation group, and a sophisticated IDN sourcing team in the same quarter (JHC; Definitive Healthcare).

2.3 Value analysis, bill-only automation and the data-armed buyer

The locus of physician-preference-item decisions has moved to professionalized value analysis committees that demand outcomes evidence and total-cost-of-ownership math before adoption — Mayo Clinic’s formulation is representative: “Tell me what outcomes you expect to achieve, and then which of these outcomes aren’t being met.” The historically leaky bill-only implant workflow, long a source of off-contract pricing, is being closed by automation platforms, and Vizient’s Procedural Analytics is explicitly aimed at physician-level variation in procedural supply use. Clinician preference — the traditional moat around premium device pricing — is being systematically subordinated to standardization, capitated construct pricing and dual-source strategies (JHC; Casechek).

Meanwhile the buyer’s information position keeps improving. The CY2026 OPPS rule requires hospitals to publish actual allowed amounts — median, 10th and 90th percentile figures drawn from remittance data — with CEO attestation, effective January 2026 and enforced from April 2026. That data is already being packaged commercially for device price benchmarking on both sides of the table, joining established paid-price databases such as ECRI PriceGuide. Suppliers should expect counterparties to arrive with percentile-based market-price targets and to treat any quote above the median benchmark as an opening position (CMS; Gigasheet; ECRI).

3. The Reimbursement Reset: Coverage Gets Faster, Payment Gets Harder

3.1 The 2026 rate environment

The CY2026 rules set a modest baseline: a 2.6% OPPS/ASC update (total outpatient payments near $101 billion), a 2.6% inpatient update for FY2026 and 2.3% finalized for FY2027, and — for the first time — two physician conversion factors, up 3.26–3.77% for 2026 but proposed to fall 1.2–1.7% in 2027 as the temporary statutory boost expires. More consequential for device-heavy specialties is the new minus 2.5% “efficiency adjustment” applied to the work values of most procedural codes, and a practice-expense reallocation that shifts relative payment away from hospital-based proceduralists. CMS also fired a warning shot on aggressively priced device-adjacent products by unpackaging skin substitutes to a flat fee — a change it expects to cut that category’s spending by nearly 90% (McDermott+ OPPS; McDermott+ PFS; Holland & Knight).

3.2 RAPID replaces TCET; the breakthrough payment shortcuts close

The most important structural change of 2026 is the bargain CMS has struck on breakthrough technology. In April, CMS and FDA jointly announced the RAPID pathway, for breakthrough-designated devices addressing unmet Medicare needs, CMS will issue a proposed national coverage determination the same day FDA authorizes the device, compressing national coverage from nine-to-twelve months to roughly two. TCET, which had capacity for only about five devices a year, was paused for new candidates the same day. CMS Administrator Mehmet Oz framed RAPID as cutting “red tape for innovators” (CMS; MedTech Dive).

The other half of the bargain is retrenchment on payment. The FY2027 IPPS final rule eliminates the NTAP alternative pathway for breakthrough devices from FY2028, and the CY2027 OPPS proposal repeals the parallel transitional pass-through shortcut for applications received on or after October 1, 2026. The stakes are visible in the numbers: of 19 new NTAPs approved for FY2027, 16 came through the breakthrough alternative pathway. AdvaMed called the rollback “disappointing” and noted smaller companies relied on it. Congress is pulling in the opposite direction — the Ensuring Patient Access to Critical Breakthrough Products Act, which would mandate four years of automatic Medicare coverage for breakthrough devices, cleared House Ways & Means 37–3 in September 2025 and awaits floor action, with CBO scoring it at $906 million over ten years (Holland & Knight; MedTech Dive; CBO).

For pricing strategy the implication is direct: launch pricing can no longer assume an add-on payment cushion. Premium payment will once again have to be earned with evidence of substantial clinical improvement — which links reimbursement strategy back to the same evidence dossiers that value analysis committees now demand.

3.3 Utilization management moves into traditional Medicare

The WISeR model launched January 1, 2026 in six states, imposing AI-assisted prior authorization in traditional Medicare on a list of device-heavy services: skin substitutes, implanted nerve stimulators, incontinence and impotence devices, cervical fusion, knee arthroscopy and epidural steroid injections — with vendors sharing in the savings from denials. Commercial payers, meanwhile, report cutting prior authorization volume 11% under the 2025 industry pledge, though critics note denial rates have barely moved. The net effect for affected device categories is a bifurcated access environment: less friction on paper in commercial channels, materially more in traditional Medicare where it never previously existed (Federal Register; KFF; Fierce Healthcare).

Two adjacent currents matter for portfolio planning. Remote monitoring reimbursement expanded for 2026 with new short-duration RPM and RTM codes, but the CY2027 proposal swings restrictive — established-patient requirements, mandatory initiating visits and staff-employment rules that threaten third-party RPM vendor models. And the administration’s consumer-health agenda (a stated goal of a wearable on every American, plus the CMS Health Tech Ecosystem interoperability push with some 60 technology companies) is creating reimbursement-adjacent tailwinds for consumer-medical convergence devices even as traditional categories face tighter scrutiny (Nixon Law Group; Holland & Knight; Fierce Healthcare).

4. The Ambulatory Migration: Scheduled, Not Speculative

CMS has put the outpatient shift on a legislative-grade timetable. The CY2026 final rule began a three-year phase-out of the Inpatient-Only list — 271 procedures removed in 2026 (musculoskeletal first), 637 proposed for 2027, and the remaining 801 in 2028 — while adding 560 procedures to the ASC Covered Procedures List for 2026, including the cardiac catheter ablation codes electrophysiology has sought for years, with another 618 proposed for 2027. Site-neutral payment keeps advancing service line by service line: drug administration at off-campus hospital departments was cut to physician-office rates in 2026, and imaging without contrast is proposed for 2027 (McDermott+; ACC).

The buyers on the receiving end of this volume behave differently. ASC procedures cost 30–50% less than hospital equivalents, and Bain’s finding remains the essential statistic: 60% of ASC physicians would switch to a similar device from another manufacturer for a 15% discount. Physician-owners share directly in facility profitability, so price sensitivity is structural, not situational. The channel is also corporatizing fast — Tenet’s USPI spent roughly $300 million on ASC acquisitions through Q3 2025, Ascension announced a $3.9 billion AmSurg acquisition, and private equity continues rolling up specialty centers — while ASC-focused purchasing groups (HealthTrust’s AdvantageTrust, Vizient-affiliated Provista) aggregate the fragmented demand (Bain; VMG Health).

For commercial architecture this means a genuine two-price world is emerging between hospital and ambulatory settings — and ZS’s warning is apt: ASCs cannot be treated as “smaller hospitals.” Suppliers need unified pricing architectures that protect hospital net price while competing at ASC price points, ASC-specific value propositions (throughput, kit rationalisation, capitated constructs, rep-lite service models), and coverage models economical enough for a call-point universe that now exceeds 25,000 ambulatory sites — roughly five times the acute-care universe (ZS; Bain).

5. Commercial Model Innovation: Competing on Contract Architecture

5.1 Value-based and outcomes-based contracting comes of age — slowly

Risk-sharing agreements for devices remain rarer than in pharma, but the direction is unambiguous: a 2025 peer-reviewed review finds the number of US device risk-sharing agreements increasing, enabled by regulatory flexibility and better short-term outcome data capture, while identifying the persistent barriers as legal uncertainty, weak real-world measurement infrastructure and institutional reluctance to administer complex contracts. The canonical archetypes are now well established — Medtronic’s TYRX infection-cost guarantee (about 1,000 contracts against infection treatment costs of $48,000–83,000 per episode), payer deals tied to HbA1c and total cost of care, and GPO agreements with outcome-linked rebate structures (Frontiers in Public Health; MedTech Dive).

The legal architecture still runs through the warranty safe harbor: the 2020 Anti-Kickback reforms largely excluded device manufacturers from the core value-based safe harbors, leaving the broadened warranty provision — bundled item-plus-service warranties with outcome-based reimbursement up to the cost of the bundle — as the practical vehicle for most US outcome guarantees. AdvaMed continues to press for a device-specific value-based safe harbor. Meanwhile procedure-based pricing is quietly becoming standard in categories such as thrombectomy and valve repair, and Medicare’s mandatory TEAM episode model (CABG, joint replacement, spinal fusion and other device-heavy episodes, running 2026–2030) puts surgical episodes under two-sided risk nationally — expanding the natural buyer base for risk-sharing offers (MedTech Dive; ZS; Holland & Knight).

5.2 Capital without capital: as-a-service and usage-based placement

With roughly half of health systems describing their finances as constrained and more than half holding under 180 days cash, demand for off-balance-sheet structures has moved from the margins to the mainstream. The clearest datapoint is surgical robotics: of the 1,721 da Vinci systems Intuitive placed in 2025, half went out under operating leases and 28.8% of all placements were usage-based arrangements. In imaging and monitoring, the enterprise partnership is the growth vehicle — Vanderbilt’s $87 million multi-year Value Partnership with Siemens Healthineers (July 2026) covers MRI, CT, interventional and radiation oncology as a managed arrangement “rather than a traditional equipment purchase or lease,” and Philips continues to expand managed services and an open monitoring ecosystem, adding six partner companies in August 2026 (L.E.K.; Intuitive; Vanderbilt; MedTech Dive).

These structures are not merely financing conveniences. They convert an adversarial capital negotiation into a multi-year revenue relationship, embed upgrade paths and software monetisation, and — critically in the OBBBA era — let Medicaid-exposed and rural systems keep modernising when their boards have frozen capital budgets. The 94% of administrators who reported deferring equipment upgrades during the tariff shock are the addressable market for every one of these models (Premier).

5.3 AI in the commercial engine

AI adoption in MedTech commercial operations has crossed from pilots into production, unevenly. McKinsey’s survey of medtech executives found 65% already implementing generative AI and more than half deploying it in commercial workflows — account prioritisation, personalised collateral, customer service — but only 15% reporting positive P&L impact so far, with skill gaps and integration cited as the main obstacles. At the field level, an AcuityMD survey of 150 device sales reps found AI users three times more likely to meet quota, reclaiming four to six hours a week, though only 11% use AI to surface genuinely novel insight. ZS’s 2026 framing identifies the next wave as agentic: tender and rep bots, self-healing supply chains and ambient administrative workflows moving from concept into commercial operations (McKinsey; AcuityMD; ZS).

The revenue-management layer is where the money is most measurable. Ninety-nine percent of life-sciences revenue leaders expect AI to drive revenue-management value, yet about 60% still run fragmented multi-solution stacks; industry commentary pegs life-sciences revenue leakage at roughly $50 billion annually. The contract-management gap in MedTech specifically is stark: in a survey of 150+ director-and-above device executives, 100% said poor contract management leaves revenue on the table, two-thirds derive at least 70% of revenue from health-system and GPO agreements, on-contract deals close about 40% faster — and 96% still manage contracts in spreadsheets. As hospital e-sourcing, GPO analytics and CMS transparency data professionalize the buy side, an un-automated sell side is negotiating blind against counterparties with better data about its own prices than it has (Business Wire; The AI Journal).

Tender and bid digitisation completes the loop. Ninety percent of health-system leaders expected procurement digitisation to accelerate, mature digital exchanges are demonstrating 96%+ contract compliance on implant orders, and AI tender-intelligence platforms are emerging as the supplier-side response — matching capabilities to public and private bid opportunities and bringing pricing intelligence into the bid decision itself. The strategic argument, as Vamstar has put it, is that contracting needs intelligence, not just automation: knowing which tenders to bid, at what price, with what evidence, is becoming a data science discipline rather than a regional sales judgment (Vamstar).

5.4 Pricing discipline in a 2–3% world

Simon-Kucher’s benchmark series traces the arc: 81% of medtech and diagnostics firms raised prices in 2022–23 with historically high success rates, but by 2024 only half planned increases and just 6% of those aimed above inflation, with customer acceptance the dominant constraint. Its 2026 guidance is to institutionalise the price-increase process — governance, escalation rules, and evidence packages — rather than treat each cycle as a campaign. On the buy side, L.E.K. finds hospital device budgets growing only 2–4% nominally, with 80% of executives prioritising operational efficiency. In this environment the realistic sources of margin are mix, attachment (software, service, consumables), leakage recovery and contract compliance — not headline price (Simon-Kucher; L.E.K.).

6. Strategic Imperatives for 2026–2027

Seven imperatives follow from the evidence assembled above. They are written for the commercial leadership team of a device manufacturer, but the mirror image applies to any organization advising or supplying that team.

Rebuild contract language for the tariff era. The 2024–25 vintage of firm-price agreements protected buyers through the tariff shock; those agreements are now rolling off. Every renewal is a one-time opportunity to negotiate cost-adjustment mechanics — indexed clauses, tariff-triggered reopeners, country-of-origin substitution rights — before the Section 232 decision lands. Suppliers who arrive with documented, auditable cost evidence will get language; those who arrive with surcharges will get refusals, as 2025 demonstrated.

Price to the percentile, not the list. With CMS transparency files now carrying actual allowed amounts at the 10th, 50th and 90th percentiles and benchmark databases on every sourcing desk, the effective negotiation corridor for most categories is visible to both sides. Commercial teams need the same data, plus a deliberate strategy for where in the distribution each product should sit and what evidence justifies sitting above the median.

Build the two-price architecture before the volume moves. The IPO phase-out and ASC list expansions have made the ambulatory migration a schedule, not a scenario. Suppliers that wait until hospital share erodes will find themselves defending hospital net price and ASC price simultaneously with no architecture separating them. The work — segmented SKUs and kits, setting-specific value propositions, channel-appropriate service models, firewalled pricing tiers — must precede the volume shift.

Re-anchor launch economics on evidence, not add-on payments. With the NTAP and pass-through breakthrough shortcuts closing from late 2026, premium launch pricing must once again be underwritten by substantial-clinical-improvement evidence — the same evidence value analysis committees demand. Health economics and outcomes research is no longer a market-access support function; it is the pricing function’s raw material. RAPID rewards companies that design Medicare-relevant endpoints into IDE studies from the start.

Lead with risk when the customer cannot pay cash. Outcome warranties structured under the warranty safe harbor, usage-based capital placement, and enterprise value partnerships are the growth vehicles matched to a customer base with frozen capital budgets and a 2027 revenue cliff. The 28.8% usage-based share of Intuitive’s placements shows buyers will move volume to whoever removes the capital barrier.

Close the contract-intelligence gap. A sell side managing contracts in spreadsheets is structurally outgunned by a buy side running procedural analytics and e-sourcing platforms. Contract lifecycle management, price-compliance monitoring, leakage recovery and AI-assisted tender intelligence are now table stakes — the measurable margin they recover (on-contract deals closing ~40% faster; 1–4% savings ranges on reconciliation and negotiation support) typically exceeds anything achievable through headline price in a 2–3% world.

Run policy as a commercial input, not a compliance afterthought. The distance between a Federal Register notice and a P&L outcome has never been shorter: WISeR is redirecting utilization in six states today; the skin-substitute repricing vaporized a category’s economics in one rule; the Section 232 decision could reset COGS in a quarter. Commercial leadership needs a standing policy-to-pricing translation loop with owners, triggers and pre-modeled scenarios.

7. Watch List: Second Half of 2026

The following dates and decisions will shape 2027 planning assumptions. Each carries direct pricing or contracting consequences.Sources: McDermott+, Holland & Knight, Covington, CMS, Congress.gov — linked in the relevant sections above.

The through-line of 2026 is that pricing and contracting have become the strategic center of the MedTech business. Cost bases, coverage pathways, sites of care and buyer capabilities are all moving at once, and the spread between commercially sophisticated and commercially conventional manufacturers is widening into the largest controllable value driver in the industry.

The crucible does not just test, it separates.

Sources and Further Reading

Tariffs and trade policy

• One year in: How medtech companies are coping with tariff challenges — MedTech Dive (Apr 2026) [Link]
• Current and Forthcoming Section 232 Actions — Covington (Apr 2026) [Link}
• AHA Comments on Proposed Tariffs on Medications, Medical Devices (Jul 2026) [Link}
• Premier Supply Chain Special Report: Potential Impacts of Tariffs on Healthcare [Link}
• What the Supreme Court’s tariff ruling means for medtech — Medical Economics (Feb 2026)[Link}
• Section 232 probe reignites tariff uncertainty for medtech firms — Supply Chain Dive [Link}
• Medtech Tariff Refunds Ordered as New Levies Hit Industry — MD+DI (Mar 2026) [Link}

Hospital economics and procurement

• 2025 Cost of Caring Report — American Hospital Association (Mar 2026) [Link]
• Hospital finances pace below 2025 — Kaufman Hall (May 2026) [Link]
• Vizient projects continued cost pressures across the healthcare supply chain in 2026 [Link]
• Vizient Spend Management Outlook, Winter 2026 [Link]
• Premier closes $2.6B take-private deal — Healthcare Dive (Nov 2025) [Link]
• Vizient Showcases Integrated Supply Chain Capabilities at Spring IDN Summit (Apr 2026) [Link]
• Implications of the 2025 Budget Reconciliation Bill for Hospitals — KFF [Link]
• CY2026 OPPS/ASC Final Rule: Hospital Price Transparency — CMS Fact Sheet [Link]

Reimbursement and policy

• CMS Releases CY2026 OPPS/ASC Final Rule — McDermott+ [Link]
• CMS Releases CY2027 OPPS/ASC Proposed Rule — McDermott+[Link]
• CMS Releases FY2027 IPPS and LTCH Final Rule — Holland & Knight (Aug 2026) [Link]
• CMS, FDA Announce RAPID Coverage Pathway — CMS (Apr 2026) [Link]
• CMS proposes repeal of add-on payment path for breakthrough devices — MedTech Dive [Link]
• H.R. 5343 cost estimate — Congressional Budget Office (Nov 2025) [Link]
• WISeR Model — Federal Register (Jul 2025) and KFF analysis
  ASCs in 2025: A Year in Review — VMG Health (Feb 2026) [Link]

Commercial models and technology

• Medtech Trends 2026: From AI strategy to execution — ZS (Feb 2026) [Link]
• Risk-sharing agreements for medical devices — Frontiers in Public Health (Sep 2025) [Link]
• Intuitive Q4/FY2025 preliminary results (Jan 2026) [Link]
• Vanderbilt Health and Siemens Healthineers launch $87M Value Partnership (Jul 2026) [Link]
• Scaling gen AI in the medtech industry — McKinsey (May 2025) [Link]
• AI Adoption in MedTech Sales: 2026 Industry Benchmarks — AcuityMD [Link]
• State of the MedTech Customer Base: 2025 US Health System Executive Survey — L.E.K. [Link]
• Medtech’s Dilemma: ASCs Want a Discount — Bain  [Link]
• Prioritizing pricing excellence — Simon-Kucher  [Link]
• 100% of MedTech Executives Say Poor Contract Management Causes Revenue Loss — Business Wire  [Link]
• The Rise of the Tender Engine — Vamstar [Link]

This briefing was compiled in August 2026 from public sources linked throughout. Figures are as reported by the cited sources and should be re-verified before use in external materials. Nothing here is legal or investment advice.